Vixtimotamab

维莫妥单抗

Report date: 2026/03/19 16:46:35

Base Information

Drug NameVixtimotamab

Drug Alias NameT-564AMV-564

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Myeloid cell surface antigen CD33 inhibitors

TargetsT cell surface glycoprotein CD3Myeloid cell surface antigen CD33

Therapy Area/IndicationsSolid tumoursMyelodysplastic Syndromes

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmphivena Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmphivena Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursMyelodysplastic Syndromes

Other Information

ATC CodeN/A